Pulse lineResearch With Heart Logo

Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.

TitleAssociations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.
Publication TypeJournal Article
Year of Publication2012
AuthorsVirani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett ARichey, Coresh JJ, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E
Secondary AuthorsBallantyne CM
JournalCirculation
Volume125
Issue2
Pagination241-9
Date Published2012 Jan 17
ISSN1524-4539
KeywordsAdult, African Continental Ancestry Group, Aged, Atherosclerosis, Cardiovascular Diseases, Coronary Disease, European Continental Ancestry Group, Female, Follow-Up Studies, Humans, Incidence, Lipoprotein(a), Male, Middle Aged, Prognosis, Risk, Stroke
Abstract

BACKGROUND: On the basis of studies with limited statistical power, lipoprotein(a) [Lp(a)] is not considered a risk factor for cardiovascular disease (CVD) in blacks. We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study.

METHODS AND RESULTS: Plasma Lp(a) was measured in blacks (n=3467) and whites (n=9851). Hazards ratios (HRs) for incident CVD events (coronary heart disease and ischemic strokes) were calculated. Lp(a) levels were higher with wider interindividual variation in blacks (median [interquartile range], 12.8 [7.1-21.7] mg/dL) than whites (4.3 [1.7-9.5] mg/dL; P10 to ≤20 mg/dL, >20 to ≤30 mg/dL, and >30 mg/dL.

CONCLUSIONS: Lp(a) levels were positively associated with CVD events. Associations were at least as strong, with a larger range of Lp(a) concentrations, in blacks compared with whites.

DOI10.1161/CIRCULATIONAHA.111.045120
Alternate JournalCirculation
PubMed ID22128224
PubMed Central IDPMC3760720
Grant ListHHSN268201100012C / HL / NHLBI NIH HHS / United States
HHSN268201100009I / HL / NHLBI NIH HHS / United States
HHSN268201100010C / HL / NHLBI NIH HHS / United States
HHSN268201100008C / HL / NHLBI NIH HHS / United States
HHSN268201100005G / HL / NHLBI NIH HHS / United States
HHSN268201100008I / HL / NHLBI NIH HHS / United States
HHSN268201100005C / / PHS HHS / United States
HHSN268201100007C / HL / NHLBI NIH HHS / United States
HHSN268201100009C / / PHS HHS / United States
HHSN268201100011I / HL / NHLBI NIH HHS / United States
HHSN268201100011C / HL / NHLBI NIH HHS / United States
HHSN268201100010C / / PHS HHS / United States
HHSN268201100006C / HL / NHLBI NIH HHS / United States
HHSN268201100008C / / PHS HHS / United States
HHSN268201100012C / / PHS HHS / United States
K23 HL096893 / HL / NHLBI NIH HHS / United States
HHSN268201100005I / HL / NHLBI NIH HHS / United States
HHSN268201100007C / / PHS HHS / United States
HHSN268201100009C / HL / NHLBI NIH HHS / United States
HHSN268201100011C / / PHS HHS / United States
HHSN268201100005C / HL / NHLBI NIH HHS / United States
HHSN268201100007I / HL / NHLBI NIH HHS / United States
CDA 09-028 / HX / HSRD VA / United States
HHSN268201100006C / / PHS HHS / United States
5K23HL096893-02 / HL / NHLBI NIH HHS / United States
K23 HL096893-02 / HL / NHLBI NIH HHS / United States